Dermira, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. It has licensing agreements with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate in Japan; and F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DERM
CUSIPN/A
Phone650-421-7200
Debt
Debt-to-Equity Ratio2.19
Current Ratio5.17
Quick Ratio5.17
Price-To-Earnings
Trailing P/E Ratio-2.39
Forward P/E Ratio-2.03
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.54 million
Price / Sales96.61
Cash FlowN/A
Price / CashN/A
Book Value$3.59 per share
Price / Book2.92
Profitability
EPS (Most Recent Fiscal Year)($4.39)
Net Income$-303,260,000.00
Net Margins-8,823.69%
Return on Equity-95.84%
Return on Assets-33.21%
Miscellaneous
Employees162
Outstanding Shares41,850,000
Dermira (NASDAQ:DERM) Frequently Asked Questions
What is Dermira's stock symbol?
Dermira trades on the NASDAQ under the ticker symbol "DERM."
How were Dermira's earnings last quarter?
Dermira (NASDAQ:DERM) released its quarterly earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.30) by $0.09. The biopharmaceutical company had revenue of $0.30 million for the quarter. Dermira had a negative return on equity of 95.84% and a negative net margin of 8,823.69%. View Dermira's Earnings History.
What price target have analysts set for DERM?
7 brokerages have issued twelve-month price objectives for Dermira's stock. Their predictions range from $16.00 to $48.00. On average, they expect Dermira's stock price to reach $32.2857 in the next twelve months. View Analyst Ratings for Dermira.
What are Wall Street analysts saying about Dermira stock?
Here are some recent quotes from research analysts about Dermira stock:
- 1. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (5/24/2018)
- 2. Cantor Fitzgerald analysts commented, "We remain positive on DERM’s stock following a group investor dinner we held on 3/26/18 with COO & CFO Andrew Guggenhime and VP of IR Ian Clements." (3/27/2018)
- 3. Mizuho analysts commented, "We can attest that Dermira has been investing in pre-launch activities and had a strong presence at the AAD 2018 conference across all three of its key assets in acne, hyperhidrosis, and atopic dermatitis. We summarize 4Q:17 results in Exhibit 1 below. We reiterate our Buy rating in front of the binary acne read-out, which if positive, could drive significant upside to the stock. Data are expected in 1Q:18." (2/23/2018)
Who are some of Dermira's key competitors?
Some companies that are related to Dermira include Myokardia (MYOK), Deciphera Pharmaceuticals (DCPH), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Zogenix (ZGNX), Myovant Sciences (MYOV), G1 Therapeutics (GTHX), Mallinckrodt (MNK), Aimmune Therapeutics (AIMT), Biohaven Pharmaceutical (BHVN), Cambrex (CBM), ImmunoGen (IMGN), TherapeuticsMD (TXMD), Mirati Therapeutics (MRTX) and ARMO Biosciences (ARMO).
Who are Dermira's key executives?
Dermira's management team includes the folowing people:
- Mr. Thomas G. Wiggans, Co-Founder, CEO & Chairman (Age 66)
- Dr. Eugene Andrew Bauer, Co-Founder, Chief Medical Officer & Director (Age 76)
- Mr. Christopher M. Griffith, Co-Founder & Sr. VP of Corp. Devel. & Strategy (Age 42)
- Mr. Andrew L. Guggenhime, COO, CFO & Principal Accounting Officer (Age 50)
- Mr. Luis C. Peña, Chief Devel. Officer (Age 55)
Has Dermira been receiving favorable news coverage?
Headlines about DERM stock have trended somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Dermira earned a news sentiment score of 0.07 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 44.91 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Dermira's major shareholders?
Dermira's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.58%), venBio Select Advisor LLC (8.19%), Franklin Resources Inc. (2.42%), Rock Springs Capital Management LP (1.43%), Eventide Asset Management LLC (0.80%) and Dimensional Fund Advisors LP (0.77%). Company insiders that own Dermira stock include Andrew Guggenhime, Christopher M Griffith, David E Cohen, Eugene A Bauer, Fred B Craves, Luis C Pena, Thomas G Wiggans and William R Ringo. View Institutional Ownership Trends for Dermira.
Which institutional investors are selling Dermira stock?
DERM stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Platinum Investment Management Ltd., Schwab Charles Investment Management Inc., C WorldWide Group Holding A S and JPMorgan Chase & Co.. Company insiders that have sold Dermira company stock in the last year include Christopher M Griffith, David E Cohen, Eugene A Bauer and Thomas G Wiggans. View Insider Buying and Selling for Dermira.
Which institutional investors are buying Dermira stock?
DERM stock was purchased by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Eventide Asset Management LLC, Candriam Luxembourg S.C.A., Sio Capital Management LLC, Dimensional Fund Advisors LP, Rock Springs Capital Management LP, Franklin Resources Inc. and Bailard Inc.. Company insiders that have bought Dermira stock in the last two years include Fred B Craves and Thomas G Wiggans. View Insider Buying and Selling for Dermira.
How do I buy shares of Dermira?
Shares of DERM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dermira's stock price today?
One share of DERM stock can currently be purchased for approximately $10.48.
How big of a company is Dermira?
Dermira has a market capitalization of $449.87 million and generates $4.54 million in revenue each year. The biopharmaceutical company earns $-303,260,000.00 in net income (profit) each year or ($4.39) on an earnings per share basis. Dermira employs 162 workers across the globe.
How can I contact Dermira?
Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected]
MarketBeat Community Rating for Dermira (DERM)
MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe DERM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DERM will underperform the S&P 500 over the long term. You may vote once every thirty days.
